Hard to resist

Article Abstract:

A number of UK biotechnology companies involved in developing drugs have performed well in 1995. They include British Biotech which saw a rise in its share price following encouraging reports of an anti-cancer product. Oxford Molecular and Cortecs have also performed well, as has Chiroscience. Diagnostics companies have performed less consistently with Enviromed seeing a fall in its share price, and Drew Scientific seeing a share price rise but still below its placing price in May 1993.

Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Biotechnology industry, Biotechnology industries

---

Pharmaceuticals: catch the merger wave

Article Abstract:

Sandoz and Ciba have agreed to a merger which could have an impact on the pharmaceutical industry as a whole. The merger creates the second biggest drugs company world wide and large companies have a number of advantages in the industry. They have more power to buy technology from biotechnology firms, and enhanced purchasing power which helps at a time of price competition. UK pharmaceutical companies may follow this course, and analysts are assessing which companies will merge.

Mergers, acquisitions and divestments, Ciba-Geigy AG, Sandoz S.A.

---

Pharmaceuticals and healthcare

Article Abstract:

Trends affecting British pharmaceutical and healthcare firms are examined in detail.

Health care industry, Cover Story

Similar abstracts:

• Abstracts: Proteus: mad cows to the rescue. Dechra Pharmaceuticals. Dechra reigns cats and dogs
• Abstracts: Corporate reorganizations and non-cash auctions. Market valuation and merger waves. Strategic trading when agents forecast the forecasts of others
• Abstracts: A dynamic petrochemical company. Playing the ratings game. Thais celebrate TPI agreement
• Abstracts: Charitable contributions of depreciated capital assets: AMT may change the conventional planning wisdom. Capitalization of investment advisory fees: can the case be made?
• Abstracts: Hidden stars. All change, please. Industry's metal is put to the test

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.